MedTrace Logo

The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents

NCT02973061 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-08-09

No results posted yet for this study

Summary

Analysis of the short-and long-term impact of recombinant growth hormone on attention deficit and hyperactivity charachteristics in children and adolescents. This will be examined in children prior to GH therapy and 3, 6 and 12 months during treatment, by filling validated questionnaires (Vanderbilt rating scales) evaluating ADHD.

Data will be compared to healthy control group.

Conditions

  • Growth Hormone Deficiency
  • Attention Deficit Disorder
  • Idiopathic Short Stature

Interventions

OTHER

Questionnaires

All participants families will fulfill a periodic questionnaire regarding attention, behaviour.

Sponsors & Collaborators

  • Assaf-Harofeh Medical Center

    lead OTHER_GOV

Principal Investigators

  • marianna Rachmiel, md · Assaf Haroffeh Medical Center

Eligibility

Min Age
6 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Israel

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02973061 on ClinicalTrials.gov